Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Prescribing Decisions May Depend Upon Disease State

Executive Summary

Express Scripts’ Eichholz says clinicians may be less inclined to use a biosimilar in ‘life or death’ oncology indications compared to inflammatory diseases.

You may also be interested in...



Biosimilar Guidance Development Timelines Criticized By Docs And Patients

FDA's user fee deal with sponsors sets target dates for documents on interchangeability, naming and labeling, but non-industry stakeholders urge agency to accelerate their release; guidance development efforts will get boost in BsUFA II with funding for new dedicated biosimilars unit starting in fiscal year 2018.

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

Following Sandoz’s Zarxio playbook, Pfizer plans to market Inflectra while patent litigation continues; February 2017 trial on cell culture media patent could answer question of potential damages.

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel